Trial

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis

Study Director
Dr. Francesca Conradie
Start Date
8 / 2019
Trial Phase
Phase III
Trial Status
enrolling
Current Enrollment
255 - October 2021
Target Enrollment
400
Overview

6 mo BDQ DLM LZD LVX CFZ vs 9 mo South African standard of care for RIF-resistant TB.